Mesa Labs Issues First-Ever FY27 Guidance: $250-255M Revenue, $66-68M Adjusted EBITDA
MLAB sits 76% above its 52-week low of $69.51.
Summary
Mesa Labs posted 77.6% operating income growth to $8.4M on 2.6% revenue growth and issued FY27 guidance for the first time: $250-255M revenue and $66-68M adjusted EBITDA. A new $40M buyback and a $9.3M savings plan underpin the margin story.
Key Events · Earnings and Guidance · MLAB
-
Q2 Operating Income Jumps 77.6%
Revenue rose 2.6% to $62.336M while operating income climbed 77.6% to $8.388M. Diluted EPS was $0.75 versus $0.45 a year earlier, and adjusted EBITDA rose 21.1% to $17.317M, or 27.8% of revenues.
-
First-Ever FY27 Guidance Issued
Management guided FY2027 to revenues of $250-255M and adjusted EBITDA of $66-68M, versus $62.969M of adjusted EBITDA in FY2026 — roughly 5-8% growth on 0-2% revenue growth. Q3 revenue is expected about flat year-over-year on lower Clinical Genomics sales.
-
New $40M Buyback Authorized
On November 4, 2026 the board terminated the 2005 repurchase program and authorized up to $40.0M of buybacks through December 31, 2028, funded from cash on hand and operations. That sits alongside continued debt paydown of $11.406M in the quarter.
-
Savings Plan and Clinical Genomics Reshaping
The October 13, 2026 plan targets ~$9.3M of annualized cost cuts with ~$4.3M reinvested for a net ~$5.0M reduction, at pre-tax charges of ~$2.6-3.4M. Clinical Genomics revenue fell 8.8% and is expected to keep declining as the business is managed for profitability rather than scale.
Analysis · MLAB · Industrial Applications And Services
The headline number is the first full-year guidance in company history: $250-255M revenue and $66-68M adjusted EBITDA, the latter up roughly 5-8% from FY26's $62.969M. That frames the story as margin repair and capital return rather than growth, and it lands alongside a new $40M buyback and a $9.3M savings plan. Q2 operating income jumped 77.6% to $8.4M on revenue of $62.3M, but management built the guidance conservatively on a half-year of data and flagged Q3 revenue as roughly flat because Clinical Genomics is being shrunk on purpose. Revenue growth of only 0-2% is the trade-off investors are being asked to accept.
How filings like this one have moved
In the 30 days to Nov 10, 2026, 36.4% of the 3168 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MLAB was trading at $122.00 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $715.3M. The 52-week trading range was $69.51 to $144.35. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.